AUTHOR=Soberanis Pina Pamela , Lara-Mejía Luis , Matias-Cruz Venecia , Barrón Feliciano , Cardona Andrés F. , Raez Luis E. , Rios-Garcia Eduardo , Arrieta Oscar 

TITLE=Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer

JOURNAL=Frontiers in Oncology

VOLUME=Volume 13 - 2023

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1108124

DOI=10.3389/fonc.2023.1108124

ISSN=2234-943X

ABSTRACT=Abstract
Lung cancer (LC) is one of the most common causes of death worldwide. The identification of oncogene-addicted driving mutations suitable for targeted therapy have improved clinical out-comes in advanced disease. Clinical trials, on the other hand, rarely involve vulnerable groups such as pregnant women. We report a 37-year-old woman with advanced Non-Small Cell Lung Cancer (NSCLC) harboring an exon 19 deletion of EGFR treated with afatinib. After the initial treatment, the patient achieved complete response and had an unplanned pregnancy. Targeted therapy was withheld during the first trimester and resumed with osimertinib in the second tri-mester in which she developed oligohydramnios and intrauterine growth restriction (IUGR) of the baby. Osimertinib was delayed at two different times during the third trimester with com-plete resolution of the oligohydramnios. The baby was born at 37.3 weeks of gestation (WOG) with no signs of congenital disorders. After delivery, the mother restarted osimertinib and maintained a complete response. This case suggests osimertinib could be an acceptable option for tumor control during pregnancy in EGFR-mutant NSCLC. This information did not replace current recommendations for avoiding pregnancy and promoting contraceptive usage in pa-tients receiving any cancer therapy.